An Open-Label Study of the Effect of an Ophthalmic Solution on Asteroid Hyalosis
NCT ID: NCT00825942
Last Updated: 2009-04-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
20 participants
INTERVENTIONAL
2008-07-31
2009-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Open-Label Study of an Ophthalmic Solution to Reduce Intraocular Pressure in Patients With Ocular Hypertension
NCT00825396
Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
NCT02402660
Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease
NCT02435914
Randomized Study of New Formulation Ophthalmic Cysteamine Hydrochloride for Corneal Cystine Accumulation in Patients With Cystinosis
NCT00010426
CsA vs MMC for Preventing Pterygium Recurrence
NCT06944132
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
C-KAD Ophthalmic Solution
C-KAD Ophthalmic Solution
4 drops applied daily for 180 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
C-KAD Ophthalmic Solution
4 drops applied daily for 180 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Glaucoma
* Ocular hypertension
* Ocular inflammatory disorders
21 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chakshu Research, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chakshu Research, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ira Wong, MD
Role: STUDY_DIRECTOR
Chakshu Research, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mountain View Optometry and Contact Lens Clinic
Mountain View, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PCK-0108
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.